336 related articles for article (PubMed ID: 33351152)
1. Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence.
Steininger L; Chromy D; Bauer D; Simbrunner B; Binter T; Schwabl P; Schmidbauer C; Trauner M; Gschwantler M; Mandorfer M; Reiberger T
Wien Klin Wochenschr; 2021 May; 133(9-10):452-460. PubMed ID: 33351152
[TBL] [Abstract][Full Text] [Related]
2. HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic.
Hartl L; Jachs M; Bauer D; Simbrunner B; Chromy D; Binter T; Steininger L; Schwarz C; Schwarz M; Burghart L; Strassl R; Trauner M; Gschwantler M; Mandorfer M; Reiberger T
J Viral Hepat; 2022 Dec; 29(12):1062-1072. PubMed ID: 36062398
[TBL] [Abstract][Full Text] [Related]
3. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study.
Heo M; Norton BL; Pericot-Valverde I; Mehta SH; Tsui JI; Taylor LE; Lum PJ; Feinberg J; Kim AY; Arnsten JH; Sprecht-Walsh S; Page K; Murray-Krezan C; Anderson J; Litwin AH;
J Hepatol; 2024 May; 80(5):702-713. PubMed ID: 38242324
[TBL] [Abstract][Full Text] [Related]
4. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
[TBL] [Abstract][Full Text] [Related]
5. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.
Scherz N; Bruggmann P; Brunner N
Int J Drug Policy; 2018 Dec; 62():74-77. PubMed ID: 30368101
[TBL] [Abstract][Full Text] [Related]
6. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).
Rapoud D; Quillet C; Pham Minh K; Vu Hai V; Nguyen Thanh B; Nham Thi Tuyet T; Tran Thi H; Molès JP; Vallo R; Michel L; Feelemyer J; Weiss L; Lemoine M; Vickerman P; Fraser H; Duong Thi H; Khuat Thi Hai O; Des Jarlais D; Nagot N; Laureillard D;
BMJ Open; 2020 Nov; 10(11):e039234. PubMed ID: 33208326
[TBL] [Abstract][Full Text] [Related]
7. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
[TBL] [Abstract][Full Text] [Related]
8. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
9. Current hepatitis C therapy.
Husa P; Snopková S; Husa Ml P
Cas Lek Cesk; 2022; 161(2):90-93. PubMed ID: 35728965
[TBL] [Abstract][Full Text] [Related]
10. Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use.
Bota S; Razpotnik M; Hucke F; Urak C; Flatscher K; Peck-Radosavljevic M
Wien Klin Wochenschr; 2021 Jul; 133(13-14):641-646. PubMed ID: 34032930
[TBL] [Abstract][Full Text] [Related]
11. Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
Winetsky D; Burack D; Antoniou P; Garcia B; Gordon P; Scherer M
J Infect Dis; 2020 Sep; 222(Suppl 5):S392-S400. PubMed ID: 32877544
[TBL] [Abstract][Full Text] [Related]
12. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal.
Burgui C; San Miguel R; Goñi-Esarte S; Juanbeltz R; Úriz-Otano JI; Reparaz J; Sarobe M; Zozaya JM; Castilla J
Postgrad Med; 2023 May; 135(4):352-360. PubMed ID: 36305320
[TBL] [Abstract][Full Text] [Related]
14. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
[TBL] [Abstract][Full Text] [Related]
15. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
Tatara E; Gutfraind A; Collier NT; Echevarria D; Cotler SJ; Major ME; Ozik J; Dahari H; Boodram B
PLoS One; 2022; 17(3):e0264983. PubMed ID: 35271634
[TBL] [Abstract][Full Text] [Related]
16. Integration of Hepatitis C and Addiction Treatment in People Who Inject Drugs: The San Patrignano HCV-Free and Drug-Free Experience.
Piselli P; Boschini A; Gianfreda R; Nappo A; Cimaglia C; Scarfò G; Smacchia C; Paoletti R; Duehren S; Girardi E
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543741
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland.
Falcato L; Bernardini C; Bruggmann P
Int J Drug Policy; 2021 Oct; 96():103434. PubMed ID: 34511311
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
19. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.
Schmidbauer C; Schubert R; Schütz A; Schwanke C; Luhn J; Gutic E; Pirker R; Lang T; Reiberger T; Haltmayer H; Gschwantler M
PLoS One; 2020; 15(3):e0229239. PubMed ID: 32155165
[TBL] [Abstract][Full Text] [Related]
20. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
